Candel Therapeutics, Inc. CADL Proceeds From Principal Payments On Term Loan
Proceeds From Principal Payments On Term Loan at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept cadl:ProceedsFromPrincipalPaymentsOnTermLoan.
The official record: Candel Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s proceeds from principal payments on term loan.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s proceeds from principal payments on term loan?
- Candel Therapeutics, Inc. (CADL) reported proceeds from principal payments on term loan of -$4.23M in Q4 2025.
- How has Candel Therapeutics, Inc.'s proceeds from principal payments on term loan changed year-over-year?
- Candel Therapeutics, Inc.'s proceeds from principal payments on term loan decreased by 69.3% year-over-year, from -$2.5M to -$4.23M.
- What does proceeds from principal payments on term loan mean?
- This represents the cash outflows associated with the repayment of the principal balance on term loan obligations. Monitoring these payments is essential for assessing the company's debt service obligations and its overall deleveraging progress.